Biogen entered into a definitive agreement to acquire TJ Biopharma's exclusive rights to felzartamab in the Greater China Region, consolidating worldwide development and commercialization rights1
TJ Biopharma receives a $100 million upfront payment and is eligible for up to $750 million in potential commercial and sales milestone payments, plus mid-single-digit to low-double-digit percentage royalties on net sales in the region1
Felzartamab is a CD38-directed monoclonal antibody currently being evaluated in global Phase 3 clinical studies for multiple immune-mediated diseases including antibody-mediated rejection in kidney transplant recipients, IgA nephropathy (IgAN), and primary membranous nephropathy (PMN)2
Biogen previously acquired worldwide rights excluding the Greater China Region through its acquisition of HI-Bio in July 20241
TJ Bio joined Biogen-sponsored Phase 3 trials evaluating felzartamab in IgAN and PMN in China in April 20251
A Biologics License Application for felzartamab for multiple myeloma treatment was submitted by TJ Bio in December 2024 and is under review by China's National Medical Products Administration, with TJ Bio serving as manufacturer at its Hangzhou facility1
Sources:
1. https://investingnews.com/biogen-enters-into-agreement-with-tj-biopharma-for-felzartamab-assets-in-the-greater-china-region/
2. https://www.investing.com/news/company-news/biogen-acquires-china-rights-to-felzartamab-for-up-to-850m-93CH-4623086